ArticleDiscover oncology2023

High pre-chemoradiotherapy pan-immune-inflammation value levels predict worse outcomes in patients with stage IIIB/C non-small-cell lung cancer.

Erkan Topkan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.